Capmatinib in

Autor: Jürgen, Wolf, Takashi, Seto, Ji-Youn, Han, Noemi, Reguart, Edward B, Garon, Harry J M, Groen, Daniel S W, Tan, Toyoaki, Hida, Maja, de Jonge, Sergey V, Orlov, Egbert F, Smit, Pierre-Jean, Souquet, Johan, Vansteenkiste, Maximilian, Hochmair, Enriqueta, Felip, Makoto, Nishio, Michael, Thomas, Kadoaki, Ohashi, Ryo, Toyozawa, Tobias R, Overbeck, Filippo, de Marinis, Tae-Min, Kim, Eckart, Laack, Anna, Robeva, Sylvie, Le Mouhaer, Maeve, Waldron-Lynch, Banu, Sankaran, O Alejandro, Balbin, Xiaoming, Cui, Monica, Giovannini, Mikhail, Akimov, Rebecca S, Heist, Jeremy, Cetnar

Publikováno v: The New England journal of medicine. 383(10)

Among patients with non-small-cell lung cancer (NSCLC),We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients withA total of 364 patients were assigned to the cohorts. Among patients with NSCLC with aCapmatinib showed substan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::776107e1d455f68ddd285239ab211d1b
https://pubmed.ncbi.nlm.nih.gov/32877583

Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

Autor: Mark Clemons, Laurence Bourdeau, S-A Im, Barbara Pistilli, M. Campone, S Hurvitz, Noriyuki Masuda, Dalila Sellami, J. Baselga, S Le Mouhaër, Mona El-Hashimy, CL Arteaga, H. Iwata, L-M Tseng, S Chia, Banu Sankaran, Yoshinori Ito, Agnieszka Jagiełło-Gruszfeld, Zefei Jiang, Walter Jonat, M. De Laurentiis, J. Cortés, Ahmad Awada

Publikováno v: Cancer Research. 78:PD5-12

Background: BELLE-2 (NCT01610284) met its primary endpoint of a statistically significant improvement in progression-free survival (PFS) with the pan-phosphoinositide 3-kinase (PI3K) inhibitor BUP+FUL compared with PBO+FUL in postmenopausal pts with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c951b2c27b38c0b7849d23bc8c64a9c3
https://doi.org/10.1158/1538-7445.sabcs17-pd5-12

Development and validation of an LC–MS/MS based method for quantification of 25 hydroxyvitamin D2 and 25 hydroxyvitamin D3 in human serum and plasma

Autor: Banu Sankaran, Naidong Weng, Richard W Edom, D.J. Sharkey, Wenying Jian, Sheryl Sullivan, Stanley Weihua Zhang

Publikováno v: Journal of Chromatography B. 961:62-70

Vitamin D deficiency is increasing in the general population and has become a serious public health risk globally. As a reliable clinical indicator of vitamin status, 25 hydroxyvitamin D (25(OH)D) has been measured by various methods. However, the ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243a74099e47a7c1e26924e4a88a5b0f
https://doi.org/10.1016/j.jchromb.2014.05.006

Abstract A050: PIK3CA mutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2- ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies

Autor: Angelo Di Leo, Nicolas Scheuer, José Baselga, Banu Sankaran, Amanda Wang, Bharani Dharan, Mona El-Hashimy, Dalila Sellami

Publikováno v: Molecular Cancer Therapeutics. 17:A050-A050

Background: PIK3CA mutation status is a potential biomarker for treatment response to buparlisib (BUP; pan-phosphatidylinositol 3-kinase [PI3K] inhibitor) plus fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+), human epidermal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::91ce73d6b93ad68b26dc329fab16dcaf
https://doi.org/10.1158/1535-7163.targ-17-a050

Biochemical, Structural and Molecular Dynamics Analyses of the Potential Virulence Factor RipA from Yersinia pestis

Autor: Benson Lan, Celia W. Goulding, Banu Sankaran, Nicole M. Wheatley, Brian R. Atwood, Rommie E. Amaro, James B. Bliska, Céline Pujol, Nicholas Chim, Robert V. Swift, Rodrigo Torres

Publikováno v: PLoS ONE
PLoS ONE, Vol 6, Iss 9, p e25084 (2011)
Torres, Rodrigo; Swift, Robert V.; Chim, Nicholas; Wheatley, Nicole; Lan, Benson; Atwood, Brian R.; et al.(2011). Biochemical, Structural and Molecular Dynamics Analyses of the Potential Virulence Factor RipA from Yersinia pestis. PLoS ONE, 6(9), e25084. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/83t5n28m

Human diseases are attributed in part to the ability of pathogens to evade the eukaryotic immune systems. A subset of these pathogens has developed mechanisms to survive in human macrophages. Yersinia pestis, the causative agent of the bubonic plague

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7351593241215806fe1ffbe3bc53639
http://europepmc.org/articles/PMC3180442